AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A year later, in 2017, the government further withdrew his personal bodyguard service provided by the police Special Action Unit (UTK), following the earlier termination of his cook and office assistant's contracts. This decision by the government also drew criticism from various parties. However, Inspector-general of Police Mohamad Fuzi Harun denied this, stating that only ordinary police officers had been recalled, while Mahathir's bodyguard service from the elite UTK remained intact. The Prime Minister's Department also refuted this claim, stating that it was still paying for 21 staff at Mahathir's home and office. In early 2018, Mahathir was announced as Pakatan Harapan's prime ministerial candidate for the upcoming general election. Wan Azizah Wan Ismail, wife of his former political enemy Anwar, ran as his deputy. Mahathir's election promise was to seek a pardon for Anwar, in order to allow him to take over as prime minister after an interim period.
Association of Firearm and Tool Mark Examiners – International non-profit organization Canadian Identification Society Computer forensics – Branch of digital forensic science Crime science – Study of ways to prevent or reduce crime Diplomatics – Academic study of the protocols of documents (forensic paleography) Epigenetics in forensic science – Overview article Evidence packaging – Specialized packaging for physical evidence Forensic biology – Forensic application of the study of biology Forensic economics Forensic identification – Legal identification of specific objects and materials Forensic materials engineering – Branch of forensic engineering Forensic photography – Art of producing an accurate reproduction of a crime scene Forensic polymer engineering – Study of failure in polymeric products Forensic profiling – Study of trace evidence in criminal investigations Glove prints – Mark left on a surface by a worn glove History of forensic photography International Association for Identification Medical jurisprudence – Branch of science and medicine Marine forensics Outline of forensic science – Overview of and topical guide to forensic science Profiling (information science) – Creation and use of user profiles via data analysis Retrospective diagnosis – Practice of identifying an illness after the death of the patient Rapid Stain Identification Series (RSID) Scenes of crime officer – Officer who gathers forensic evidence for the British police Skid mark – Mark left by any solid which moves against another University of Florida forensic science distance education program
=== Characters === Nathan Byrn: The 17-year-old protagonist. He has straight black hair, olive skin and black eyes. He looks like his father. Raised in a family of White witches, but with a Black witch father, he is a Half Code. He can self-heal extraordinarily fast. Jessica Byrn: Nathan's oldest half-sister who hates him. She later becomes a Hunter. Arran Byrn: Nathan's half-brother, with whom Nathan has a loving relationship. Deborah Byrn: Nathan's half-sister. She (like Arran) loves Nathan. Marcus Edge: Nathan's father, the most feared Black witch of all time. He killed Nathan's siblings' father, among numerous others. His Gift is transforming into animals but he has also stolen Gifts from many other witches by killing them and eating their hearts. Cora Byrn: Nathan's mother, a White witch who died by suicide. Her gift was healing. Gabriel Boutin: A Black witch stuck in the body of a Fain. He helps Mercury to get Nathan to her in order to get his witch body back and later falls in love with Nathan. Annalise O'Brien: A White witch, some months older than Nathan. She runs away from her cruel family. She and Nathan were in love as young teens. Soul O'Brien: The uncle of Annalise and a White witch. Mercury: A powerful Black witch who has stolen the blood of every witch family. Rose: A White witch and Mercury's assistant, who always blushes and giggles. Celia: A White witch, Nathan's mentor with whom he was sent to live. She appears to treat Nathan cruelly and even would lock him in a cage.
=== Major hormones === Neurokinin B (a tachykinin peptide) and kisspeptin (a neuropeptide), both present in KNDy neurons of the hypothalamus, are critical parts of the control system that switches on the release of GnRH at the start of puberty. GnRH (gonadotropin-releasing hormone) is a peptide hormone released from the hypothalamus which stimulates gonadotrope cells of the anterior pituitary. LH (luteinizing hormone) is a larger protein hormone secreted into the general circulation by gonadotrope cells of the anterior pituitary gland. The main target cells of LH are the Leydig cells of testes and the theca cells of the ovaries. LH secretion changes more dramatically with the initiation of puberty than FSH, as LH levels increase about 25-fold with the onset of puberty, compared with the 2.5-fold increase of FSH. FSH (follicle stimulating hormone) is another protein hormone secreted into the general circulation by the gonadotrope cells of the anterior pituitary. The main target cells of FSH are the ovarian follicles and the Sertoli cells and spermatogenic tissue of the testes. Testosterone is a steroid hormone produced primarily by the Leydig cells of the testes, and in lesser amounts by the theca cells of the ovaries and the adrenal cortex. Testosterone is the primary mammalian androgen and the "original" anabolic steroid. It acts on androgen receptors in responsive tissue throughout the body. Estradiol is a steroid hormone produced by aromatization of testosterone. Estradiol is the principal human estrogen and acts on estrogen receptors throughout the body.
== Registration of PKMM rejected == In 1950, the Federation of Malaya Government rejected the registration of the Malay Nationalist Party of Malaya (Parti Kebangsaan Melayu Malaya, PKMM) as a legitimate political party. PKMM had two wings, namely Angkatan Pemuda Insaf and Angkatan Wanita Sedar. Initially, PKMM did not have communist leanings. After Mokhtaruddin Lasso was elected as the first PKMM president in October 1946, this party was influenced with communism. The Young Malays Union (Kesatuan Melayu Muda, KMM) merged with PKMM, and Burhanuddin al-Helmy became the second PKMM president. Burhanuddin led PKMM toward the formation of Melayu Raya, a merger of Indonesia and Malaya. In December 1947, Ishak Haji Mohamed became the third PKMM president and PKMM switched from communism to nationalism. PKMM tended against United Malays National Organisation (UMNO) and colonisation. PKKM established the Pusat Tenaga Rakyat (PUTERA), a conglomeration of radical Malay Political Parties and then merged with the All-Malaya Council of Joint Action (AMCJA) which thoroughly opposed the 1948 Federation Agreement for the foundation of the Federation of Malaya. PKMM accused officials selected in the Federation of Malaya of being "puppets" of the "Colonial Office". For PKMM, there was no basis in "preparing Malaya as a democratic government".
Sources: en.wikipedia.org
== Inhibitors == Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.
=== Pathological mechanism === HLA-B27 is the most researched HLA-B allele due to its high relationship with spondyloarthropathies. Although it is not apparent how HLA-B27 promotes disease, theories exist and can be divided between antigen-dependent and antigen-independent categories.
== Exercise == Biomechanical studies have demonstrated that, depending on the activity and the size of a woman's breast, when she walks or runs braless, her breasts may move up and down by 4 to 18 centimetres (1.6 to 7.1 in) or more, and also oscillate side to side. Researchers have also found that as women's breast size increased, they took part in less physical activity, especially vigorous exercise. Few very-large-breasted women jogged, for example. To avoid exercise-related discomfort and pain, medical experts suggest women wear a well-fitted sports bra during activity.
==== Corporate logos on pills ==== A number of ecstasy manufacturers brand their pills with a logo, often that of an unrelated corporation. Some pills depict logos of products or media popular with children, such as Shaun the Sheep.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.